ObsEva: Xoma will be receiving full worldwide rights on ebopiprant

ObsEva (OBSV) announced that Xoma (XOMA) will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2alpha receptor antagonist, following the termination of the license agreement with Organon (OGN). After positive Phase 2a results in November 2020, ObsEva granted a license to Organon in July 2021 for the global development, manufacturing, and commercial rights to ebopiprant. In November 2022, ObsEva sold and assigned to Xoma all its rights to ebopiprant, including the company’s license agreement with Organon, and the intellectual property estate. In addition to the $15M received in upfront proceeds from the sale, ObsEva was eligible to receive certain milestones under the license agreement with Organon for ebopiprant. These contingent milestone payments will no longer be available to ObsEva, but the company will evaluate strategic and partnership options with Xoma. “We view the termination of the license agreement as a unique opportunity for a company to in-license ebopiprant rights from Xoma and are prepared to leverage ObsEva’s expertise in the upcoming months for any purpose that could support ebopiprant further development,” said Fabien de Ladonchamps, CEO.